News | Radiation Therapy | April 27, 2017

Early Stereotactic Radiosurgery Improves Outcomes for Nonfunctioning Pituitary Macroadenoma Patients

Multi-center cohort study finds SRS earlier following surgery decreases risk of radiographic progression versus delayed radiotherapy treatment

Early Stereotactic Radiosurgery Improves Outcomes for Nonfunctioning Pituitary Macroadenoma Patients

April 27, 2017 — Jason P. Sheehan, M.D., Ph.D., FAANS, winner of the Leksell Radiosurgery Award, presented his research on stereotactic radiosurgery (SRS) in patients with nonfunctioning pituitary macroadenomas during the 2017 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, April 22-26 in Los Angeles.

Stereotactic radiosurgery (SRS) is frequently used to treat residual or recurrent nonfunctioning pituitary macroadenomas. There is no consensus as to whether SRS should be used early after surgery or if radiosurgery should be withheld until there is evidence of imaging-defined tumor progression. Given the high incidence of adenoma progression after subtotal resection, the study evaluated the effect of timing of radiosurgery on outcome.

A multi-center study of patients with nonfunctioning pituitary macroadenomas who underwent partial resection followed by SRS from 1987 to 2015 was conducted at nine institutions of the International Gamma Knife Research Foundation. Patients were matched by adenoma types and radiosurgical parameters and stratified based on the interval between resection and radiosurgery. Operative results, imaging and clinical outcomes were compared across groups following early (SRS delivered <= 6 months from the time of resection) or late (SRS delivered > 6 months from the time of resection) radiosurgery.

After matching, 222 patients met the study criteria and were grouped based on early or late SRS following transsphenoidal surgery. There was a greater risk of tumor progression in the late radiosurgical group over a median imaging follow-up period of 68.5 months. No significant difference in occurrence of post-GKRS endocrinopathy was observed. Thirty percent of patients without endocrinopathy in the early cohort developed new endocrinopathies during the follow-up period versus 27 percent in the late cohort. Fourteen percent of the early group and 25 percent of the late group experienced resolution of endocrine dysfunction since original presentation.

Results of the study indicate that early SRS decreases the risk of radiographic progression of sub-totally resected nonfunctioning pituitary macroadenomas compared to expectant management followed by late radiosurgery. Delaying radiosurgery may place patients at increased risk for long-term adenoma progression. Early radiosurgery may be preferred in nonfunctioning pituitary adenoma patients with residual tumor after surgery and a life expectancy of five or more years.  The timing of radiosurgery does not appear to significantly affect the rate of delayed endocrinopathy.

The author block included: Jonathan Pomeraniec; Hideyuki Kano; Zhiyuan Xu; Brandon Nguyen; Zaid Siddiqui; Danilo Silva; Mayur Sharma; Christian Iorio-Morin; Amparo Wolf; John Jane Jr.; Inga Grills; David Mathieu; Douglas Kondziolka; Cheng-Chia Lee; Gene Barnett; L. Dade Lunsford; Chih-Chun Wu; Chris Cifarelli; Tomas Chytka; Hesham Radwan; Jonathan Cohen; and Robert Dallapiazza

For more information: www.aans.org

Related Content

Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...